Market Pulse
Daily · Sep 17, 2026 · data.go.kr + ECOS
KOSPI
6,715.41
-2.56 (-0.04%)
KOSDAQ
822.18
+6.20 (+0.76%)
KOSPI 200
1,058.27
-1.78 (-0.17%)
USD/KRW
1,382.20
185750KOSPI·Aug 05, 2025
Focus on the potential of HDAC6 inhibitor
Mirae Asset Securities published a company analysis report on Chong Kun Dang Pharmaceutical Corp. (185750) titled "Focus on the potential of HDAC6 inhibitor".
Summary
Covers Chong Kun Dang Pharmaceutical Corp. (185750).
Covered stock
More on 185750
Limited earnings improvement, but pipeline development on trackMirae Asset Securities · Aug 24, 2026Atrial fibrillation asset newly reflected in pipeline valueMirae Asset Securities · Feb 27, 2026Earnings Stable; R&D Also Steadily in ProgressKB Securities · Nov 04, 2025Focus on clinical trial plans for CKD-510Mirae Asset Securities · Feb 04, 2025